EverSource Wealth Advisors’s Akebia Therapeutics AKBA Stock Holding History

EverSource Wealth Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$732	Buy	+527	New	+$724	﹤0.01%	3960
2025 Q4	–	Sell	-469	Closed	-$1.28K	–	4274
2025 Q3	$1.28K	Sell	469 -64	-12%	-$213	﹤0.01%	3683
2025 Q2	$1.94K	Buy	533 +290	+119%	+$797	﹤0.01%	3519
2025 Q1	$467	Buy	243 +229	+1,636%	+$467	﹤0.01%	3480
2024 Q4	$27	Buy	+14	New	+$24	﹤0.01%	3691
2023 Q1	–	Sell	-1,250	Closed	-$721	–	2378
2022 Q4	$721	Hold	1,250	–	–	﹤0.01%	2156
2022 Q3	$0	Hold	1,250	–	–	﹤0.01%	1962
2022 Q2	$0	Hold	1,250	–	–	﹤0.01%	1702
2022 Q1	$1K	Hold	1,250	–	–	﹤0.01%	1621
2021 Q4	$3K	Buy	+1,250	New	+$3.41K	﹤0.01%	1388

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

EverSource Wealth Advisors's AKBA Position: Q1 2026 in Review

EverSource Wealth Advisors opened a new position in Akebia Therapeutics (AKBA) in Q1 2026: 527 shares worth $732. The stake represents ﹤0.01% of the portfolio and ranks #3960 among its holdings. This is a return to the name: EverSource Wealth Advisors previously reported a position in AKBA as recently as Q3 2025.

EverSource Wealth Advisors first reported a position in AKBA in Q4 2021 and has held it in 10 quarters since. The position peaked at $3K in Q4 2021. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

EverSource Wealth Advisors held 527 shares of Akebia Therapeutics worth $732 as of Q1 2026.
Akebia Therapeutics was a new EverSource Wealth Advisors position in Q1 2026.
Akebia Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q1 2026, its #3960 holding.
EverSource Wealth Advisors first reported a position in Akebia Therapeutics in Q4 2021 and has held it in 10 quarters since.
EverSource Wealth Advisors's Akebia Therapeutics position peaked at $3K in Q4 2021.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on EverSource Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.